Hybridon, MethylGene deal

HYBN created MethylGene, a Canadian subsidiary to develop HYBN's antisense technology to treat cancer. The technology inhibits DNA methyltransferase, a regulatory protein overexpressed in certain tumors. HYBN and scientists at McGill University have been working on the technology for four years. ...